Log In
BCIQ
Print this Print this
 

oral solithromycin (CEM-101) (formerly OPT-1068)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionOral formulation of a fluoroketolide/macrolide antibiotic
Molecular Target Ribosomal 50S subunit
Mechanism of ActionRibosomal 50S subunit inhibitor
Therapeutic ModalityMacrocycle

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$70.0M

$10.0M

$60.0M


 Deals Details
Get a free BioCentury trial today